Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 1004-1014

  Treré, Davide ^a   Montanaro, L ^a   Ceccarelli, C ^a   Barbieri, S ^a   Cavrini, G ^a   Santini, D ^a   Taffurelli, M ^a   Derenzini, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Adjuvant therapy; Bcl2 expression; Breast cancer; Immunohistochemistry; Prognosis; Real time RT PCR

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE; MESSENGER RNA; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PAGET NIPPLE DISEASE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; VALIDATION PROCESS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 34447315829     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm074     Document Type: Article

References (40)

1. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 28: 1322-1326.
2. Karakas T, Maurer U, Weidmann E et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998; 9: 159-165.
3. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl 2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-272.
4. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005; 41: 858-887.
5. Castle VP, Heidelberger KP, Bromberg J et al. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N myc amplification. Am J Pathol 1993; 143: 1543-1550.
6. Eid H, Gulyas M, Geczi L et al. Expression of bcl-2 in testicular carcinoma: Correlation with tumor progression and MDR1/Pgp. Cancer 1998; 83: 331-336.
7. Rosser CJ, Reyes AO, Vakar-Lopez F et al. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 1-6.
8. Campos L, Renault JP, Sabido O et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
9. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 1993; 4: 41-47.
10. Pezzella F, Turley H, Kuzu I et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
11. Ohbu M, Saegusa M, Kobayashi N et al. Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer 1997; 79: 1287-1293.
12. Dimitrakakis C, Kymionis G, Diakomanolis E et al. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol 2000; 77: 129-136.
13. Divito KA, Berger AJ, Camp RL et al. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res 2004; 64: 8773-8777.
14. Charpin C, Garcia S, Bonnier P et al. bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: Correlation with 10-year follow-up. J Clin Oncol 1998; 16: 2025-2031.
15. Hellemans P, van Dam PA, Weyler J et al. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995; 72: 354-360.
16. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Patrol 1994; 145: 1191-1198.
17. Le MG, Mathieu MC, Douc-Rasy S et al. c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: Evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer 1999; 84: 562-67.
18. Charpin C, Garcia S, Bouvier C et al. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 1997; 28: 289-296.
19. Silvestrini R, Veneroni S, Daidone MG et al. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
20. Yang QF, Sakurai T, Yoshimura G et al. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res Treat 2000; 61: 211-216.
21. Berardo MD, Elledge RM, de Moor C et al. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998; 82: 1296-1302.
22. Gasparini G, Barbareschi M, Doglioni C et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995; 1: 189-198.
23. McCallum M, Baker C, Gillespie K et al. A prognostic index for operable, node-negative breast cancer. Br J Cancer 2004; 90: 1933-1941.
24. Elledge RM, Green S, Howes L et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. J Clin Oncol 1997; 15: 1916-1922.
25. Gee JM, Robertson JF, Ellis IO et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994; 59: 619-628.
26. Schiller AB, Clark WS, Cotsonis G et al. Image cytometric bcl-2:bAx and bcl-2:bCl-x ratios in invasive breasC carcinoma: correlation with prognosis. Cytometry 2002; 50: 203-209.
27. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
28. Faccioli S, Chieco P, Gramantieri L et al. Cytometric measurement of cell proliferation in echo-guided biopsies from focal lesions of the liver. Mod Pathol 1996; 9: 120-125.
29. Ellis IO, Bartlett J, Dowsett M et al. Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57: 233-237.
30. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 87-220.
31. Treré D, Ceccarelli C, Migaldi M et al. Cell proliferation in breast cancer: A major determinant of clinical outcome in node-positive, but not in node-negative patients. Appl Immunohistochem Mol Morphol 2006; 14: 314-323.
32. Lipponen P, Pietilainen T, Kosma VM et al. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995; 177: 49-55.
33. van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 1998; 77: 789-796.
34. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996; 95: 513-517.
35. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
36. Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994; 1: 61-65.
37. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002; 97: 584-592.
38. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR et al. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 2003; 9: 1161-1170.
39. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-3907.
40. Yang Q, Sakurai T, Yoshimura G et al. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol Rep 2003; 10: 121-125.